Canaan Partners

Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins. The company’s lead product candidates include ARV-110, a proteolysis-targeting chimera (PROTAC) currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. Additionally, Arvinas is developing other PROTACs aimed at degrading various androgen receptor mutations and has initiatives focused on treating neurodegenerative diseases, including tauopathies. Arvinas collaborates with major pharmaceutical companies such as Pfizer, Genentech, Roche, and Bayer to advance its innovative therapeutic approaches. Founded in 2015, Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening conditions through its unique protein degradation technology.

Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins. The company’s lead product candidates include ARV-110, a proteolysis-targeting chimera (PROTAC) currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. Additionally, Arvinas is developing other PROTACs aimed at degrading various androgen receptor mutations and has initiatives focused on treating neurodegenerative diseases, including tauopathies. Arvinas collaborates with major pharmaceutical companies such as Pfizer, Genentech, Roche, and Bayer to advance its innovative therapeutic approaches. Founded in 2015, Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening conditions through its unique protein degradation technology.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins. The company’s lead product candidates include ARV-110, a proteolysis-targeting chimera (PROTAC) currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. Additionally, Arvinas is developing other PROTACs aimed at degrading various androgen receptor mutations and has initiatives focused on treating neurodegenerative diseases, including tauopathies. Arvinas collaborates with major pharmaceutical companies such as Pfizer, Genentech, Roche, and Bayer to advance its innovative therapeutic approaches. Founded in 2015, Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening conditions through its unique protein degradation technology.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Tallan is a technology services provider based in Hartford, Connecticut, with over 30 years of experience in custom application development and data management. The company delivers tailored solutions that enhance operational efficiency, reduce costs, improve customer experiences, and drive revenue growth. Tallan specializes in various areas, including Portals and Collaboration, Business Intelligence, Application Integration, Mobile Platforms, User Experience, Ecommerce, Web Development, Government Solutions, Cloud Services, and IT Strategy. Additionally, the company has developed a bug and defect database called Bug Appliance, which helps track and manage issues in software development projects. As a recognized Microsoft National Solution Provider, Tallan has achieved multiple Gold Competencies in Microsoft technologies, underscoring its expertise and commitment to quality in the technology sector.